Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2025)
Historic Research & Development for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $23.3 million.
- Arcturus Therapeutics Holdings' Research & Development fell 4055.04% to $23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.5 million, marking a year-over-year decrease of 3004.27%. This contributed to the annual value of $195.2 million for FY2024, which is 157.34% up from last year.
- Arcturus Therapeutics Holdings' Research & Development amounted to $23.3 million in Q3 2025, which was down 4055.04% from $29.6 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' Research & Development's 5-year high stood at $58.7 million during Q2 2024, with a 5-year trough of $23.3 million in Q3 2025.
- Over the past 5 years, Arcturus Therapeutics Holdings' median Research & Development value was $43.8 million (recorded in 2024), while the average stood at $41.9 million.
- In the last 5 years, Arcturus Therapeutics Holdings' Research & Development skyrocketed by 53218.39% in 2021 and then plummeted by 4958.33% in 2025.
- Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Research & Development stood at $32.6 million in 2021, then decreased by 17.32% to $27.0 million in 2022, then soared by 35.73% to $36.6 million in 2023, then rose by 19.55% to $43.8 million in 2024, then crashed by 46.86% to $23.3 million in 2025.
- Its last three reported values are $23.3 million in Q3 2025, $29.6 million for Q2 2025, and $34.9 million during Q1 2025.